GILEAD SCIENCES SL

Gilead Sciences filed a patent infringement lawsuit against Laurus Labs in 2018 over generic versions of tenofovir disoproxil fumarate (TDF), a cornerstone HIV and hepatitis B treatment.

Geron Corporation has appointed Harout Semerjian as President and CEO effective August 7, 2025, bringing over 30 years of hematology and oncology experience from leadership roles at Novartis, Ipsen, and GlycoMimetics.

Gilead Sciences' HIV prevention drug Yeztugo is performing "well ahead of expectations" following its recent US and European launch, with unaided awareness reaching 72% compared to typical industry launch levels.

The FDA has approved a new indication for Biktarvy to treat HIV patients with treatment history who are not virologically suppressed and are restarting antiretroviral therapy.

ViiV Healthcare has expanded its voluntary licensing agreement with the Medicines Patent Pool to allow generic production of cabotegravir for HIV treatment in 133 countries, including all low-income and Sub-Saharan African nations.

Arcus Biosciences announced that quemliclustat, an investigational small-molecule CD73 inhibitor, received FDA orphan drug designation for treating pancreatic cancer.

Gilead Sciences is conducting two clinical studies evaluating sacituzumab govitecan-hziy for advanced triple-negative breast cancer and various solid tumors including cervical cancer.

Assembly Biosciences has dosed the first participant in the Phase 1b portion of its clinical trial evaluating ABI-1179, a long-acting herpes simplex virus helicase-primase inhibitor for recurrent genital herpes.

The FDA has approved 84 drugs in 2025 so far, marking the second-highest total for this period despite major organizational changes including 3,500 staff layoffs.

Assembly Biosciences reported positive Phase 1b results for ABI-4334, a next-generation capsid assembly modulator, showing potent antiviral activity against chronic hepatitis B virus infection.